Your browser doesn't support javascript.
loading
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.
Nissen, Steven E; Linnebjerg, Helle; Shen, Xi; Wolski, Kathy; Ma, Xiaosu; Lim, Shufen; Michael, Laura F; Ruotolo, Giacomo; Gribble, Grace; Navar, Ann Marie; Nicholls, Stephen J.
Afiliação
  • Nissen SE; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
  • Linnebjerg H; Eli Lilly and Company, Indianapolis, Indiana.
  • Shen X; Eli Lilly and Company, Indianapolis, Indiana.
  • Wolski K; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
  • Ma X; Eli Lilly and Company, Indianapolis, Indiana.
  • Lim S; Eli Lilly and Company, Indianapolis, Indiana.
  • Michael LF; Eli Lilly and Company, Indianapolis, Indiana.
  • Ruotolo G; Eli Lilly and Company, Indianapolis, Indiana.
  • Gribble G; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
  • Navar AM; Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
  • Nicholls SJ; Victorian Heart Institute, Monash University, Clayton, Australia.
JAMA ; 330(21): 2075-2083, 2023 12 05.
Article em En | MEDLINE | ID: mdl-37952254
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apolipoproteínas A / Lipoproteína(a) / RNA Interferente Pequeno Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apolipoproteínas A / Lipoproteína(a) / RNA Interferente Pequeno Idioma: En Ano de publicação: 2023 Tipo de documento: Article